Urothelial carcinoma can arise in the bladder, ureters, renal pelvis, or urethra and is frequently diagnosed when it has already invaded surrounding tissue or spread to distant organs. For many years, platinum-based chemotherapy formed the backbone of treatment for advanced disease, but its effectiveness is limited by resistance, relapse, and the health status of patients who may be older or affected by kidney impairment and other illnesses. The combination examined in GUARDIANS brings together two distinctly engineered medicines. Enfortumab vedotin is an antibody–drug conjugate that recognizes Nectin-4, a protein commonly present at high levels on urothelial cancer cells, while pembrolizumab is an immune checkpoint inhibitor that helps restore the capacity of T cells to attack malignant cells.

Enfortumab vedotin operates as a molecular delivery system. Its antibody component binds to Nectin-4 on the tumor-cell surface and is internalized, carrying with it the cytotoxic payload monomethyl auristatin E, or MMAE. Once released inside the cell, MMAE disrupts microtubules, structures required for cell division, eventually triggering cell death. Pembrolizumab works through a different pathway. Tumors can suppress immune activity by engaging the PD-1 receptor on T cells through its ligands, PD-L1 and PD-L2. By blocking PD-1, pembrolizumab can release this inhibitory signal. The combination therefore pairs direct drug-mediated killing with immune reactivation, a strategy that may produce complementary or synergistic antitumor effects.

The importance of the GUARDIANS analysis lies in its real-world design. Randomized trials are essential for establishing whether a treatment works under standardized conditions, but participants in those studies are often selected according to strict criteria involving organ function, performance status, previous therapies, and the absence of serious coexisting disease. Routine clinical practice is less predictable. Physicians treat patients with varying levels of frailty, diverse patterns of metastasis, different prior treatments, and medical conditions that may influence both benefit and toxicity. By assembling data from multiple institutions, the GUARDIANS investigators sought to determine whether the clinical promise of enfortumab vedotin plus pembrolizumab remained visible when the regimen was used across a wider spectrum of patients.

The study’s central assessment focused on effectiveness and safety, the two measures that ultimately determine whether a cancer therapy can be integrated into routine care. Effectiveness in this setting is generally evaluated through outcomes such as tumor response, disease control, progression-free survival, and overall survival. These measures address different questions: whether tumors shrink, how long the cancer remains stable or controlled, how quickly the disease progresses, and how long patients live after treatment begins. Safety analysis examines treatment-related adverse events, dose interruptions, reductions, and discontinuations. Such details are particularly important for a combination in which adverse effects can arise from either the antibody–drug conjugate, the immune therapy, or the interaction between treatment and a patient’s underlying vulnerabilities.

The findings provide real-world support for the clinical activity of the combination in advanced urothelial carcinoma, while also illustrating the practical toxicities that oncologists must manage. The regimen is not a simple infusion with a uniform risk profile. Enfortumab vedotin can be associated with peripheral neuropathy, skin reactions, fatigue, appetite changes, hyperglycemia, and ocular complications, reflecting the effects of its cytotoxic payload and its distribution through the body. Pembrolizumab can produce immune-related inflammation affecting organs such as the thyroid, lungs, liver, colon, kidneys, or skin. These reactions occur when immune activation extends beyond the tumor and can require corticosteroids, treatment interruption, or permanent discontinuation in serious cases.

The real-world perspective is especially relevant for patients who would not necessarily resemble the participants in the pivotal trials that established the combination. Advanced urothelial carcinoma commonly affects older adults, many of whom have reduced renal function because of age, previous surgery, urinary obstruction, or other chronic disease. Some have received earlier chemotherapy or immunotherapy, while others begin treatment with extensive metastatic disease and limited physical reserve. Observational cohorts cannot replace randomized comparisons because treatment decisions are not assigned by chance and may be influenced by disease severity or physician preference. However, they can reveal how treatment selection, dose management, and adverse-event monitoring function in the environment where most patients actually receive care.

The GUARDIANS results also contribute to a broader shift in the therapeutic logic of urothelial cancer. Instead of relying exclusively on sequential treatment—first chemotherapy, then immunotherapy, followed by a targeted agent—clinicians increasingly use biologically complementary combinations earlier in the disease course. The rationale is to expose cancer cells to multiple pressures before resistant clones become dominant. Yet combination therapy also raises an important clinical question: does improved tumor control come at the cost of tolerability? Real-world evidence can help answer that question by documenting how often patients require modifications, whether toxicity accumulates over time, and which baseline characteristics may identify people more likely to benefit or experience complications.

For patients and physicians, the practical message is not that enfortumab vedotin plus pembrolizumab is universally suitable, but that it has become a significant treatment option whose value depends on careful selection and active monitoring. Before and during therapy, clinicians may need to assess blood glucose, neurologic symptoms, skin changes, vision, liver function, thyroid activity, and signs of immune-mediated inflammation. Early recognition can be decisive: neuropathy may require dose adjustment, severe rash may demand interruption, and immune-related organ injury may need prompt immunosuppression. The regimen’s effectiveness must therefore be considered alongside the patient’s performance status, comorbidities, previous treatment exposure, goals of care, and ability to attend frequent monitoring visits.

As the GUARDIANS cohort adds evidence from routine practice, it strengthens the case for continuing to study how this dual-action treatment performs across different populations and health systems. Future research will need to clarify which molecular features predict response, whether specific metastatic sites behave differently, how long treatment should continue, and how the combination compares with emerging antibody–drug conjugates and other targeted therapies. Long-term follow-up will also be important for understanding delayed immune toxicities, persistent neuropathy, and outcomes after treatment discontinuation. For now, the multi-institutional experience places enfortumab vedotin plus pembrolizumab among the most consequential developments in advanced urothelial carcinoma, while emphasizing that the success of precision oncology depends not only on attacking the cancer, but also on managing the patient.

Subject of Research: Effectiveness and safety of enfortumab vedotin plus pembrolizumab in a real-world population with urothelial carcinoma.

Article Title: Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS)

Article References: Published in Cancer Immunology, Immunotherapy; DOI: 10.1007/s00262-026-04448-2

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04448-2

Keywords: Urothelial carcinoma, bladder cancer, enfortumab vedotin, pembrolizumab, antibody–drug conjugate, immune checkpoint inhibitor, Nectin-4, PD-1, real-world evidence, GUARDIANS cohort, cancer immunotherapy, treatment safety

In most clinical pathways, surgery to remove the bladder is recommended after failure of BCG because durable cancer control is difficult to achieve with existing options. Here, investigators evaluated whether the experimental therapy could induce strong tumor regression within the bladder while maintaining an acceptable safety profile.

The trial enrolled 115 patients across 41 medical centers in North America, Asia, and Australia. Participants had high-risk disease, including carcinoma in situ, and were treated with cretostimogene grenadenorepvec administered directly into the bladder.

Results were striking for the primary outcome of complete response, defined by the absence of detectable cancer after treatment. Overall, 75% of patients achieved a complete response, and many of those responses remained durable for more than two years. Two years after starting treatment, an estimated 81% of patients had not required cystectomy.

Durability analyses suggested that among those with complete disappearance of cancer, about 60% remained cancer-free at the two-year mark. One patient reportedly remained free of recurrence for more than four years after completing therapy, indicating that prolonged remission is possible in a subset of patients.

Safety findings indicated that most treatment-related adverse effects were mild and temporary, largely involving bladder-related symptoms. Importantly, researchers reported no severe treatment-related side effects, supporting the tolerability of repeated intravesical dosing.

Investigators emphasize that these outcomes may shift management for BCG-unresponsive patients by adding a bladder-sparing alternative without compromising cancer control. They also caution that the therapy has not been directly compared with other bladder-preserving strategies in randomized trials.

The study was funded by CG Oncology, and the therapy remains investigational pending further evaluation.

Subject of Research: Bladder cancer immunotherapy (intravesical oncolytic immunotherapy)
Article Title: Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial
Web References: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00194-4/fulltext
References: Mayo Clinic–led phase 3 trial results published in The Lancet Oncology (BOND-003 Cohort C)
Keywords: bladder cancer, BCG-unresponsive, intravesical therapy, oncolytic immunotherapy, cretostimogene grenadenorepvec, bladder sparing, phase 3 trial, carcinoma in situ, cystectomy

Type I interferons are a group of cytokines known for their role in the immune response to viral infections and tumor growth. Among these, IFN-β has emerged as a critical player in the modulation of immune pathways, activating a series of cellular processes that can ultimately lead to the destruction of cancer cells. The research team set out to investigate how IFN-β can be effectively used in a clinical setting, particularly targeting the challenging area of bladder cancer.

Bladder cancer, noted for its high recurrence rate and resistance to conventional therapies, poses a significant therapeutic challenge. The need for novel treatment options is paramount, as existing modalities often fall short of curative outcomes. This calls for an exploration of innovative approaches, such as the application of type I interferons, which demonstrate not only anti-viral properties but also substantial anti-tumor activities.

The comprehensive study conducted by Hesse and colleagues involves meticulous in vitro experiments designed to examine the direct effects of IFN-β on bladder cancer cell lines. The results indicated that treatment with IFN-β leads to enhanced apoptosis, a form of programmed cell death, which is essential for eliminating cancer cells. Moreover, the team discovered that IFN-β induces the expression of various immune-modulating factors, suggesting its dual action of directly targeting tumor cells and engaging the broader immune system.

Upon administering IFN-β, the researchers observed a significant upregulation of major histocompatibility complex (MHC) molecules on the surface of bladder cancer cells. This facilitated an improved recognition of tumor cells by cytotoxic T lymphocytes, a subtype of immune cells crucial in the body’s defense against cancer. The enhanced visibility of cancer cells may provide an advantageous context for the overall anti-tumor immune response.

Furthermore, the investigation highlighted that IFN-β administration stimulates the production of pro-inflammatory cytokines and chemokines, which serve to recruit other immune cells to the tumor microenvironment. The activated immune cells then work in concert to eradicate tumor cells, showcasing the potential for utilizing IFN-β as a therapeutic agent in bladder cancer.

The findings underline the importance of integrating immune-modulating agents like IFN-β into existing treatment regimens. Combined with standard approaches such as chemotherapy or novel immunotherapies, IFN-β could enhance the overall effectiveness of treatment strategies against this recalcitrant cancer type.

As researchers delve deeper into the mechanistic understanding of IFN-β, there remains a strong emphasis on evaluating its safety profile and long-term effects in clinical trials. The promising results obtained by Hesse et al. pave the way for future studies aimed at validating the clinical relevance of these findings. If successful, such endeavors may lead to novel combination therapies that harness the potential of IFN-β.

Importantly, the research also brings to light potential biomarkers that could predict which patients are likely to respond favorably to IFN-β treatment. This personalized medicine approach could optimize therapeutic outcomes, ensuring that patients receive the most effective treatment tailored to their tumor characteristics and immune system profiles.

While the results are encouraging, the researchers acknowledge that more extensive investigations are required to further elucidate the full range of IFN-β’s effects on bladder cancer. The heterogeneity observed in tumor responses suggests that individual patient factors, including genetic diversity and immune system variability, will play a crucial role in shaping therapeutic strategies.

In conclusion, the work presented by Hesse et al. represents a pivotal step forward in the application of immune therapy for bladder cancer. By effectively utilizing type I interferon β, the research team has opened new avenues for combating this formidable disease. With ongoing efforts to translate these findings into clinical practice, the hope is that these insights will ultimately lead to improved survival rates and quality of life for bladder cancer patients worldwide.

Ultimately, this research reinforces the ongoing commitment within the scientific community to uncover innovative cancer treatments that adapt to the complexities of tumor biology and leverage the body’s innate immune capabilities. The journey of translating basic science into clinical application is fraught with challenges, but the potential rewards of such endeavors make it a pursuit worth undertaking.

As the horizon of cancer therapy continually stretches, advances like those seen with IFN-β serve as a beacon of hope for developing effective strategies against bladder cancer and possibly other malignancies, igniting excitement for what lies ahead in the field of cancer treatment.

Subject of Research: Type I-interferon β and its effects on bladder cancer cells

Article Title: Type I-interferon β induces a strong anti-tumour response in bladder cancer cells.

Article References:
Hesse, M., Iltzsche, M., Nahhas, D. et al. Type I-interferon β induces a strong anti-tumour response in bladder cancer cells.
J Cancer Res Clin Oncol 152, 35 (2026). https://doi.org/10.1007/s00432-025-06409-1

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s00432-025-06409-1

Keywords: type I interferon, bladder cancer, immunotherapy, anti-tumor response, cytokines, apoptosis, immune modulation.

CAR T cell therapy, a revolutionary cancer treatment that engineers a patient’s own immune cells to target malignant cells, has achieved spectacular success in hematologic malignancies but has faced formidable barriers in solid tumors such as bladder cancer. One of the key challenges lies in the insufficient and heterogeneous expression of antigens that CAR T cells can recognize and target. NECTIN4, a cell adhesion molecule commonly overexpressed in bladder tumors, represents a promising antigenic target; however, its variable expression limits therapeutic consistency. The new findings shine a light on the capacity to elevate NECTIN4 levels by fine-tuning intracellular signaling pathways, providing a strategic lever to amplify CAR T cell recognition and lethality.

The investigators homed in on the peroxisome proliferator-activated receptor gamma (PPARγ) pathway, a nuclear receptor intricately involved in lipid metabolism, inflammation, and cellular differentiation. While PPARγ has been extensively studied in metabolic diseases, its role in the modulation of tumor antigen expression had remained largely unexplored. By pharmacologically activating PPARγ, the researchers observed a robust increase in NECTIN4 surface expression on bladder cancer cells. This upregulation created a more conspicuous target for CAR T cells engineered to recognize NECTIN4, markedly boosting their cytotoxic activity against tumor cells.

Intriguingly, the study elucidates the molecular underpinnings of this modulation, revealing that PPARγ activation triggers transcriptional programs that remodel tumor cell phenotypes. The researchers employed RNA sequencing and chromatin immunoprecipitation assays to map the downstream effectors, identifying that PPARγ activation enhances NECTIN4 gene transcription via promoter binding and epigenetic changes favoring gene accessibility. These insights not only clarify the mechanism of action but also underscore the potential for fine-tuning tumor antigen landscapes through targeted pathway modulation.

In preclinical models, including patient-derived xenografts and organoids, the combinatorial treatment comprising PPARγ agonists alongside NECTIN4-specific CAR T cells achieved impressive tumor regression. This synergy translated into prolonged survival and reduced tumor burden without exacerbating toxicity, pointing toward a feasible therapeutic window. Notably, the modulation approach did not adversely alter the overall viability or phenotype of the T cells themselves, alleviating concerns regarding off-target effects or exhaustion.

The team’s meticulous exploration extended beyond efficacy to address critical hurdles in CAR T therapy such as tumor heterogeneity and immune evasion. By rendering the antigen more uniformly expressed across tumor populations, the PPARγ pathway modulation mitigated one of the canonical resistance mechanisms that hamper immunotherapy success. These findings hint at broader applicability, suggesting that strategic modulation of nuclear receptor pathways could be leveraged to enhance antigen density in other solid tumors resistant to immunotherapeutic interventions.

Furthermore, the authors discuss the translational potential of existing clinically approved PPARγ agonists, historically used in metabolic disorders such as diabetes, as adjuvant agents in immunotherapy regimens. This repurposing avenue presents an accelerated path to clinical trials, bypassing the protracted drug development timeline. The concept of harnessing metabolic regulators to sensitize tumors to immune attack represents a paradigm shift, aligning metabolic modulation with immuno-oncology for maximal therapeutic impact.

Additionally, this work highlights a critical convergence of metabolic signaling and immune recognition, a frontier area in cancer biology gaining momentum. It underscores the intricate crosstalk between tumor cell-intrinsic pathways and extrinsic immune surveillance, intricately orchestrated at the molecular level. By strategically manipulating this crosstalk, therapy can be tailored not merely to kill cancer cells but to reprogram their intrinsic identity, rendering them more vulnerable to immune-mediated clearance.

The implications extend to biomarker development as well. NECTIN4 expression levels, modulated by PPARγ activity, could serve as dynamic biomarkers to monitor therapeutic response or to stratify patients for personalized CAR T therapy regimens. This adaptive biomarker model advocates for real-time monitoring of tumor antigen status, facilitating iterative treatment adjustments that optimize clinical outcomes.

From a broader perspective, the study presents a compelling case for integrative oncology approaches that combine molecular biology, immunology, and pharmacology to overcome entrenched clinical challenges. Such interdisciplinary strategies promise to unlock new therapeutic windows previously deemed inaccessible. The convergence of CAR T cell engineering and pathway-specific tumor modulation embodies the cutting edge of precision medicine, delivering hope for patients with recalcitrant bladder cancers.

The research also addresses safety considerations by demonstrating minimal off-target PPARγ activation effects in non-malignant cells within the tumor microenvironment. This selectivity is crucial as indiscriminate modulation could potentially alter immune cell subsets or promote adverse metabolic shifts. The careful dosing and timing parameters established in the study provide a blueprint for balancing efficacy with safety in subsequent clinical translations.

An exciting frontier raised by these findings is the prospect of designing next-generation CAR T therapies coupled with built-in molecular modulators, enabling autonomous tumor antigen upregulation upon CAR engagement. Such ‘smart’ CAR T cells could dynamically adjust their targets, circumventing antigen loss variants that frequently lead to relapse. This visionary approach could herald a transformative leap in solid tumor immunotherapy.

Moreover, the study opens avenues for combining PPARγ pathway modulation with other immunomodulatory agents such as checkpoint inhibitors or cytokine therapies, potentially orchestrating a multi-pronged assault on bladder tumors. The combinatorial landscape enabled by this discovery expands the arsenal against a notoriously tough-to-treat cancer type, offering hope for durable remissions.

In conclusion, the elegant work by Chang and colleagues represents a watershed moment in bladder cancer research, illustrating the profound therapeutic synergy achievable by integrating molecular pathway modulation with immune cell engineering. By enhancing NECTIN4 expression through PPARγ activation, the study overcomes intrinsic barriers to effective CAR T cell therapy in solid tumors, offering a beacon of hope in the oncology community. As this promising avenue advances toward clinical validation, it sets a precedent for harnessing the molecular malleability of tumors to amplify immunotherapy’s curative potential.

Subject of Research: Enhancing CAR T cell therapy efficacy in bladder cancer through modulation of the PPARγ pathway to upregulate NECTIN4 expression.

Article Title: Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.

Article References:
Chang, K., Delavan, H.M., Yip, E. et al. Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Nat Commun 16, 8215 (2025). https://doi.org/10.1038/s41467-025-62710-0

Image Credits: AI Generated

For over three decades, BCG has been recognized as the earliest immunotherapy approved by the U.S. Food and Drug Administration (FDA) against cancer. Its clinical application in bladder cancer has been predominantly thought to be due to direct infection of tumor cells, which consequently activates an immune attack localized strictly to the bladder environment. However, the precise immunological dynamics and contributions of bacterial versus tumor-targeted immune responses have remained a subject of intense scientific inquiry and debate.

The investigators behind this modern study set out to transcend traditional paradigms by probing the systemic effects that BCG exerts, especially beyond the bladder. Their research revealed that BCG, rather than operating solely as a local agent, travels through the body and seeds the bone marrow, the cradle of immune cell genesis. This translocation leads to a profound ‘training’ or reprogramming of progenitor cells, particularly hematopoietic stem and progenitor cells, shifting the developmental trajectory of myeloid cells in a way that enhances their anti-tumor capabilities.

The innate immune system, a first responder endowed with rapid but nonspecific defense mechanisms, coexists with the adaptive immune system, which provides targeted and memory-based responses. The compelling data from this study illuminate how BCG reprogramming predominantly invigorates myeloid cells, critical components of innate immunity, to mount a stronger, more effective anti-cancer response. This systemic immune modulation contrasts with prior assumptions that the therapeutic effects of BCG were restricted to adaptive immunity mechanisms centered on T cell activation within the bladder microenvironment.

Cutting-edge methodologies underpinned these discoveries, notably the employment of Progenitor Input Enrichment single cell sequencing (PIE-seq), an innovative technique developed at Weill Cornell Medicine. This technology enabled an unprecedented analysis of rare hematopoietic stem and progenitor cells from peripheral blood, circumventing the need for invasive bone marrow sampling. By capturing the transcriptional and epigenetic remodeling that occurs after BCG treatment, researchers characterized the molecular signatures of reprogrammed stem cells whose progeny ultimately display enhanced tumor-fighting functions.

In mouse models, the presence of BCG in bone marrow was confirmed through culture assays, firmly establishing that the bacterium directly reaches and colonizes immune cell niches. The systemic re-education of the hematopoietic compartment potentiates the immune system’s ability to combat cancer beyond the local microenvironment. Importantly, human clinical samples from bladder cancer patients treated with intravesical BCG corroborated these findings, highlighting similar hematopoietic reprogramming events in patients.

Beyond elucidating the intrinsic biology of BCG, the study also explored combinatorial treatment strategies. In murine experiments, pairing BCG with checkpoint inhibitors—a class of immunotherapy drugs designed to unleash T cells by disabling immunological "brakes"—produced synergistic effects. Tumors in mice subjected to combined therapy exhibited greater regression and prolonged survival compared to either monotherapy. This synergy underscores the potential to integrate innate immune training with adaptive immune activation, maximizing therapeutic outcomes.

Checkpoint inhibitors have revolutionized cancer therapy by enabling the immune system to recognize and attack tumors more vigorously. However, their efficacy varies widely among patients and cancer types. The discovery that BCG-induced myeloid cell reprogramming can prime the immune microenvironment to be more receptive to checkpoint blockade offers a strategic pathway to enhance patient responses and overcome resistance.

Historically, MSK has been at the forefront of immunotherapy innovation, dating back to seminal work in the 1950s that first demonstrated the immune system’s capacity to fight cancer through BCG vaccination models. These foundational studies paved the way for contemporary immunotherapies such as CAR T cell therapies and cancer vaccines. This latest research extends MSK’s legacy by revealing the nuanced systemic effects of BCG, breathing new life into a therapy over a century in the making.

Looking forward, this paradigm shift invites a reevaluation of how localized immunotherapies like BCG might be harnessed to reprogram hematopoiesis and systemic immunity. Investigations are anticipated to focus on whether similar immune training mechanisms can be activated in other cancer types and what molecular signals mediate hematopoietic reprogramming. Moreover, understanding the duration and sustainability of these trained immune states could inform optimized treatment regimens and schedules.

This research elevates our comprehension of the complex interplay between microbes and the immune system within oncological contexts. It challenges previous dogma by demonstrating that microbial immunotherapies can function beyond sites of administration, invoking systemic hematopoietic shifts that potentiate innate immunity. The clinical implications are profound: combining microbial training agents with advanced immunotherapies may become a cornerstone strategy to amplify anti-cancer immunity.

In sum, the discovery that BCG extends its therapeutic reach by reprogramming bone marrow hematopoiesis to enhance myeloid-driven anti-tumor responses reveals untapped dimensions of cancer immunotherapy. As immuno-oncology continues to expand, this insight offers a promising avenue to develop more effective, durable, and broadly applicable cancer treatments. Continued exploration of microbial influences on the immune system could unlock novel interventions, marking a new chapter in the fight against cancer.

Subject of Research: BCG vaccine’s systemic effects on hematopoiesis and innate immune system reprogramming to enhance anti-tumor immunity.

Article Title: Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity

News Publication Date: 29-May-2025

Web References:

• Cancer Cell Article
• PIE-seq Methodology

References:

• Original research published in Cancer Cell, DOI: 10.1016/j.ccell.2025.05.002

Image Credits: Memorial Sloan Kettering Cancer Center

Keywords: Cancer research, Immunotherapy, Cancer immunotherapy

BCG is derived from a weakened strain of the bacterium Mycobacterium bovis, originally developed as a vaccine against tuberculosis and administered extensively to children worldwide. In bladder cancer therapy, however, BCG is introduced into the bladder at much higher concentrations. Traditionally, its mechanism was thought to rely on direct infection of cancer cells, which would then attract and activate immune cells to target the tumor. This paradigm suggested a localized immune activation. Yet, until now, the full spectrum of immune responses triggered by BCG, especially the systemic facets, remained inadequately explored.

Dr. Michael Glickman, a physician-scientist and acting director of the Marie-Josée Kravis Center for Cancer Immunobiology at MSK, emphasized how BCG stands as a classic example of a treatment validated by clinical outcomes long before its molecular and cellular underpinnings were understood. His team’s recent publication in Cancer Cell reveals that beyond its local bladder effects, BCG reprograms hematopoietic stem and progenitor cells (HSPCs) within the bone marrow. This reprogramming bolsters the generation of myeloid cells—a crucial subset of innate immune cells—thereby amplifying the body’s broader immune competence against tumors.

This expansion of the innate immune response is particularly significant because the innate immune system serves as the body’s first responder, offering rapid and generalized defense mechanisms. Unlike the adaptive immune system—which relies on prior exposure and develops highly specific responses—innate immunity can provide an immediate antitumor effect. The study demonstrates that BCG’s immunotherapeutic benefit partly arises from its ability to enhance this innate arm of immunity, essentially “training” bone marrow progenitors to yield immune cells better equipped to detect and destroy cancer cells.

The investigative team combined meticulous analyses of blood samples from bladder cancer patients undergoing BCG therapy with advanced studies using mouse models of bladder cancer. Leveraging a sophisticated technique known as Progenitor Input Enrichment single-cell sequencing (PIE-seq), developed at Weill Cornell Medicine, the researchers could deeply profile rare circulating HSPCs from patients’ blood draws. This innovative approach bypassed the need for more invasive bone marrow biopsies and provided unprecedented insights into cellular reprogramming following BCG treatment.

Findings revealed significant shifts in gene expression within these progenitor cells, indicating that BCG therapy redefines the developmental trajectory of immune cells in the bone marrow. The newly programmed myeloid cells emerging from these progenitors displayed enhanced tumor-fighting capacities, supporting the concept that BCG acts systemically, far beyond the bladder, to orchestrate a refined innate immune response.

Complementing their patient data, mouse model studies established that BCG bacteria administered intravesically could translocate from the bladder to the bone marrow, where live bacteria could be cultured. This observation decisively confirmed that BCG acts not just as a local stimulus but also as a systemic immunomodulator. Consistent with prior observations of BCG vaccination reducing susceptibility to viral infections, the researchers postulate that BCG’s capacity to prime bone marrow progenitors underlies broad immune benefits extending beyond cancer therapy.

The research also explored therapeutic synergies between BCG and checkpoint inhibitors, another class of immunotherapy that functions by lifting inhibitory signals on T cells, thus reigniting their ability to recognize and attack tumors. Mouse experiments demonstrated that combining BCG with checkpoint inhibitors resulted in superior tumor shrinkage and prolonged survival compared to either therapy alone. This synergy arises because BCG-stimulated myeloid cells enhance T cell activation, effectively creating a mutually reinforcing immune environment for cancer eradication.

Dr. Steven Josefowicz, associate professor of pathology and laboratory medicine at Weill Cornell Medicine and co-senior author on the study, noted that these findings have profound implications for the future of cancer immunotherapy. They suggest that strategically targeting the bone marrow to reprogram innate immunity can substantially augment the efficacy of existing treatments. This strategy might open avenues for improving immunotherapies across various cancer types, fostering immune resilience at the fundamental cellular level.

Despite the promising nature of these discoveries, several questions remain. Future research will need to address how best to harness and optimize this bone marrow reprogramming therapeutically and whether intravesical administration of BCG can potentiate immunotherapy responses in cancers beyond the bladder. As Dr. Glickman remarks, while these concepts are compelling, translating them into clinical practice requires careful, rigorous investigation.

This study was made possible by the extensive collaboration between clinical scientists and researchers, supported by ongoing collection of patient samples through MSK urologic surgeon Dr. Eugene Pietzak, as well as contributions from McGill University. The multidisciplinary nature of this research exemplifies the integration of clinical insights with cutting-edge molecular techniques necessary to unlock the complexities of cancer immunotherapy.

In conclusion, this research reinvigorates our understanding of BCG as not just a bladder-specific treatment but as a potent systemic immune trainer. By revealing the pivotal role of the bone marrow in mediating BCG’s effects, it opens new horizons for designing therapies that not only attack tumors directly but also harness the body’s intrinsic defense architectures for sustained and enhanced cancer control.

Subject of Research: Cancer immunotherapy; BCG therapy; innate immunity; hematopoietic stem and progenitor cells; bone marrow reprogramming; bladder cancer

Article Title: BCG Immunotherapy Reprograms Bone Marrow Progenitors to Enhance Innate Immunity Against Cancer

News Publication Date: 29-May-2025

Web References:

• https://www.mskcc.org/cancer-care/types/bladder/treatment/bacillus-calmette-guerin-therapy
• http://dx.doi.org/10.1016/j.ccell.2025.05.002
• https://www.sciencedirect.com/science/article/pii/S0092867423007961?via%3Dihub

References: The publication in Cancer Cell, May 29, 2025

Keywords: Immunology; Cancer immunotherapy; Medical treatments; Innate immune system; BCG therapy; Hematopoietic stem cells; Bone marrow; Bladder cancer; Checkpoint inhibitors